One-Trick Pony Boan Biotech Files for Hong Kong IPO Into Tough Market
The biotech company is awaiting approval on a second drug to drive up revenue as it firms its foothold in a competitive landscape Key Takeaways: Boan Biotechnology sells only one…
RELATED ARTICLES
-
Impression Dahongpao trapped in its one-trick pony performance
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Cancer drug maker Biostar shines on Hong Kong market debut
2563.HK
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
- Innogen Pharma jostles for a slice of the weight-loss market
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
